# Gary Glick

> Gary D. Glick is a chemist and company founder based in Boston. A former University of Michigan faculty member and founder of its Chemical Biology Doctoral Program, he founded Lycera, First Wave Bio, IFM and Odyssey and co-founded Scorpion. He is currently founder, president and CEO of Odyssey, interim CEO and executive chair of CHARM, and a scientific advisor to Aktis.

- **Role:** Founder, President and Chief Executive Officer at Odyssey Therapeutics; Interim CEO and Executive Chair at CHARM Therapeutics
- **Organizations:** Odyssey Therapeutics, CHARM Therapeutics, Scorpion Therapeutics, IFM Therapeutics, Lycera Corporation, First Wave Bio, University of Michigan, Aktis Oncology
- **Education:** B.A. in Chemistry, Rutgers University, Ph.D. in Organic Chemistry, Columbia University, NIH postdoctoral fellowship in organic chemistry, Harvard University
- **Known for:** Founded Michigan’s Chemical Biology Doctoral Program., Author of more than 100 papers and inventor on 54 issued US patents, according to Aktis’s current biography., Recipient of Sloan, Camille Dreyfus Teacher-Scholar and NSF Young Investigator recognition; AAAS fellow.

## Career timeline

- **1988** — Completed a Columbia Ph.D. with W. Clark Still.
- **1990** — Joined the University of Michigan chemistry faculty after postdoctoral work with Jeremy R. Knowles at Harvard.
- **2006** — Founded Lycera based on academic research.
- **2015** — Founded IFM Therapeutics and served as CEO.
- **2016** — Retired from Michigan effective December 31; became emeritus.
- **2019** — Became executive chairman of IFM in December, following his CEO tenure.
- **2020** — Co-founded Scorpion in February and became its founding CEO.
- **2021** — Left Scorpion’s CEO role in February; founded Odyssey in April. Odyssey announced a $218 million Series A in December.
- **2022** — Joined CHARM as executive chair; Odyssey announced a $168 million Series B in October.
- **2025** — Became CHARM’s interim CEO in June.
- **2026** — Odyssey began trading on Nasdaq as ODTX on May 8; its IPO closed May 11.

## Achievements

- Founded Michigan’s Chemical Biology Doctoral Program.
- Author of more than 100 papers and inventor on 54 issued US patents, according to Aktis’s current biography.
- Recipient of Sloan, Camille Dreyfus Teacher-Scholar and NSF Young Investigator recognition; AAAS fellow.
- Scorpion grew to nearly 50 employees and raised $270 million across two financings during his founding CEO tenure.
- Odyssey’s IPO and concurrent private placement, including partial exercise of the underwriters’ option, generated $314.8 million in gross proceeds in 2026.

## Latest updates

- **2026-09** — Odyssey management was scheduled for the Stifel virtual investor forum on September 23.
- **2026-06** — Odyssey reported $314.8 million in gross IPO and concurrent private-placement proceeds including partial exercise of the underwriters’ option.
- **2026-05** — Odyssey began Nasdaq trading under ODTX on May 8 and closed its IPO on May 11.

## Links

- Website: https://odysseytx.com/leadership/
- LinkedIn: https://www.linkedin.com/in/gary-d-glick-71145015b

---

Profile page: https://yespress.io/gary-glick
Published by YesPress — https://yespress.io
Last updated: 2026-10-11